ABT-737

04/01/2012 - "Our results also suggest that 1h could have therapeutic potential against ABT-737 refractory cancer."
03/01/2020 - "Despite the dramatic efficacy of ABT-737, a large percentage of cancer cells ultimately become resistance to this drug. "
01/01/2019 - "In vitro cytotoxicity assays demonstrated that the addition of the ABT compounds, specifically ABT-737, sensitized the different tumors to IT treatment, and improved the IC50 values of 9.2.27-PE38KDEL up to >1,000-fold. "
01/01/2013 - "A BH3 mimetic, ABT-737, has demonstrated efficacy in several forms of cancers. "
01/01/2011 - "The BH3 mimetic ABT-737, which can induce apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional chemotherapeutic agents in multiple cancers. "

06/01/2012 - "Therapeutic efficacy of ABT-737, a Bcl-2 inhibitor, in a canine melanoma cell line."
11/15/2012 - "To determine if the anti-apoptotic BCL-2 repertoire established the cell death threshold and chemoresistance in melanoma, a novel treatment strategy was designed to inhibit the anti-apoptotic BCL-2 members with ABT-737. "
06/01/2012 - "In the present study, we evaluated the inhibitory activity of ABT-737 on the survival of a canine melanoma cell line (MCM-N1). "
02/01/2013 - "The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance."
01/01/2013 - "Because the over expression of Mcl-1 is frequently observed in melanoma, specifically targeting of Mcl-1 may overcome the resistance of ABT-737. "

04/01/2012 - " control mice and CI-1040-treated mice exhibited progressive leukemia growth, ABT-737, and to a significantly greater extent, ABT-737+CI-1040 exerted major anti-leukemia activity. "
01/01/2014 - "Our study suggests that ABT-737 synergistically enhances the cytotoxic effect of DNR in AML cell lines and therefore may be useful to overcome chemoresistance of leukemia patients."
06/15/2012 - "In this study, we investigated potential mechanisms of resistance to ABT-737 in leukemia cell lines. "
03/01/2011 - "We describe the in vitro studies to demonstrate the activity and drug combinability of ABT-737 against MLL rearranged leukemia cells. "
03/01/2011 - "This study focuses on the effects of ABT-737 on leukemia cells with MLL rearrangement and identifies some of the biological correlates of its activity. "

07/01/2014 - "Ku70 knockdown not only promotes Mcl-1 turnover but also enhances antitumor efficacy of the BH3-mimetic ABT-737 in human lung cancer xenografts. "
11/01/2008 - "For example, ABT-737 is able to induce apoptosis when used as a single agent to treat leukemic and lung cancer cells and has also been shown to synergize with conventional chemotherapeutic agents in several cancer types. "
09/05/2008 - "We demonstrate that a combination of ABT-737 and TRAIL induced significant cell death in multiple cancer types, including renal, prostate, and lung cancers, although each agent individually had little activity in these tumor cells. "
07/01/2011 - "Moreover, the increased anticancer efficacy of gemcitabine combined with ABT-737 was further validated in a human lung cancer 95-D xenograft model in nude mice. "
01/01/2016 - "The results of this preclinical study support the feasibility of further investigation of the perifosine plus ABT-737 regimen in future lung cancer clinical tests."

11/18/2008 - "In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas."
04/22/2010 - "To study potential mechanisms of resistance to ABT-737, we derived resistant lines from initially sensitive OCI-Ly1 and SU-DHL-4 lymphoma cell lines via long-term exposure. "
08/01/2014 - "Of particular interest, we observed a synergistic effect of those compounds with ABT-737 in Bfl-1 overexpressing lymphoma cell lines. "
04/22/2010 - "Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1."
02/26/2009 - "However, in contrast to the reported binding specificity data, Emu-myc/Bcl-w lymphomas were insensitive to ABT-737 used alone or in combination with HDACi, indicating that the regulatory activity of ABT-737 is restricted to Bcl-2 and Bcl-X(L). "